Amgen (AMGN)
(Delayed Data from NSDQ)
$298.62 USD
+0.12 (0.04%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $301.05 +2.43 (0.81%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Brokerage Reports
Amgen Inc. [AMGN]
Reports for Purchase
Showing records 321 - 340 ( 429 total )
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Lifesciences Review: Down but not out
Provider: HYBRIDAN LLP
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Industry Report ; PHARMA & BIOTECH; This report contains brief updates on the following: VRX, PFE, NVO, MNTA, CORT, BIIB, AMGN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: ZACKS INVESTMENT RESEARCH
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Imlygic + Keytruda Combination Data Underscore the Power of I/O Combinations
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M